September 17, 2008
Seattle Genetics to Present at the UBS Global Life Sciences Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2008 UBS Global Life Sciences Conference on Tuesday, September 23, 2008, at 10:00 a.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City.
A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section.
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has four product candidates in ongoing clinical trials: SGN-40, SGN-33, SGN-35 and SGN-70. SGN-40 is being developed under a worldwide collaboration with Genentech. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma.